[1] |
CHEN D W, LANG B H H, MCLEOD D S A. Thyroid cancer[J]. Lancet, 2016, 388(10061):2783-2795.
doi: S0140-6736(16)30172-6
pmid: 27240885
|
[2] |
中华医学会内分泌学分会, 中华医学会外科学分会甲状腺及代谢外科学组, 中国抗癌协会头颈肿瘤专业委员会, 等. 甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J]. 国际内分泌代谢杂志, 2023, 43(2):149-194.
|
|
Endocrinology Branch of the Chinese Medical Association, Thyroid and Metabolic Surgery Group of the Surgery Society of the Chinese Medical Association, Head and Neck Tumor Professional Committee of China Anti-Cancer Association, et al. Diagnosis and treatment guidelines for thyroid nodules and differentiated thyroid cancer (second edition)[J]. Int J Endocrinol Metabolism, 2023, 43(2):149-194.
|
[3] |
赫捷, 李进, 程颖. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12):1164-1201.
|
|
HE J, LI J, CHEN Y. Chinese Society of Clinical Onco-logy (CSCO) diagnosis and treatment guidelines for differentiated thyroid cancer 2021[J]. J Cancer Control Treat, 2021, 34(12):1164-1201.
|
[4] |
HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
doi: 10.1089/thy.2015.0020
URL
|
[5] |
HURLEY J R. Historical note: TSH suppression for thyroid cancer[J]. Thyroid, 2011, 21(11):1175-1176.
doi: 10.1089/thy.2011.2111.com
pmid: 22050035
|
[6] |
MAZZAFERRI E L, JHIANG S M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer[J]. Am J Med, 1994, 97(5):418-428.
doi: 10.1016/0002-9343(94)90321-2
pmid: 7977430
|
[7] |
中国抗癌协会甲状腺癌专业委员会. 中国抗癌协会甲状腺癌整合诊治指南(2022精简版)[J]. 中国肿瘤临床, 2023, 50(7):325-330.
|
|
Thyroid Cancer Professional Committee of China Anti-Cancer Association. Integrated diagnosis and treatment guidelines for thyroid cancer of China Anti-Cancer Association (2022 Simplified Edition)[J]. Chin J Clin Oncol, 2023, 50(7):325-330.
|
[8] |
田文, 张浩. 分化型甲状腺癌术后管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9):1021-1028.
|
|
TIAN W, ZHANG H. Chinese expert consensus on postoperative management of differentiated thyroid cancer (2020 edition)[J]. Chin J Pract Surg, 2020, 40(9):1021-1028.
|
[9] |
程若川. 分化型甲状腺癌术后促甲状腺激素抑制治疗现状和思考[J]. 中国实用外科杂志, 2023, 43(4):391-396.
|
|
CHENG R C. Current status and considerations of post-operative thyroid stimulating hormone inhibition therapy for differentiated thyroid cancer[J]. Chin J Pract Surg, 2023, 43(4):391-396.
|
[10] |
MING J, ZHU J Q, ZHANG H, et al. A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study)[J]. BMC Endocr Disord, 2021, 21(1):208.
doi: 10.1186/s12902-021-00871-x
pmid: 34670546
|
[11] |
PRAW S S, BRENT G A. Approach to the patient with a suppressed TSH[J]. J Clin Endocrinol Metab, 2023, 108(2):472-482.
doi: 10.1210/clinem/dgac635
URL
|
[12] |
BIONDI B, COOPER D S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer[J]. Thyroid, 2010, 20(2):135-146.
doi: 10.1089/thy.2009.0311
URL
|
[13] |
FREUDENTHAL B, WILLIAMS G R. Thyroid stimulating hormone suppression in the long-term follow-up of differentiated thyroid cancer[J]. Clin Oncol (R Coll Radiol), 2017, 29(5):325-328.
doi: S0936-6555(16)30482-4
pmid: 28043744
|
[14] |
GRANI G, RAMUNDO V, VERRIENTI A, et al. Thyroid hormone therapy in differentiated thyroid cancer[J]. Endocrine, 2019, 66(1):43-50.
doi: 10.1007/s12020-019-02051-3
pmid: 31617165
|
[15] |
HEEMSTRA K A, HAMDY N A, ROMIJN J A, et al. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma[J]. Thyroid, 2006, 16(6):583-591.
doi: 10.1089/thy.2006.16.583
pmid: 16839260
|
[16] |
KU E J, YOO W S, LEE E K, et al. Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2021, 106(12):3655-3667.
doi: 10.1210/clinem/dgab539
pmid: 34302730
|
[17] |
BIONDI B, COOPER D S. Thyroid hormone suppression therapy[J]. Endocrinol Metab Clin North Am, 2019, 48(1):227-237.
doi: 10.1016/j.ecl.2018.10.008
URL
|
[18] |
LAMARTINA L, GRANI G, DURANTE C, et al. Follow-up of differentiated thyroid cancer - what should (and what should not) be done[J]. Nat Rev Endocrinol, 2018, 14(9):538-551.
doi: 10.1038/s41574-018-0068-3
pmid: 30069030
|
[19] |
XIA Q, DONG S, BIAN P D, et al. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma[J]. Eur Arch Otorhinola-ryngol, 2016, 273(4):1037-1043.
|
[20] |
JONKLAAS J, SARLIS N J, LITOFSKY D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy[J]. Thyroid, 2006, 16(12):1229-1242.
doi: 10.1089/thy.2006.16.1229
pmid: 17199433
|
[21] |
KLUBO-GWIEZDZINSKA J, AUH S, GERSHENGORN M, et al. Association of thyrotropin suppression with survival outcomes in patients with intermediate and high-risk differentiated thyroid cancer[J]. JAMA Netw Open, 2019, 2(2):e187754.
doi: 10.1001/jamanetworkopen.2018.7754
URL
|
[22] |
ABIRI A, GOSHTASBI K, TORABI S J, et al. Outcomes and trends of treatments in high-risk differentiated thyroid cancer[J]. Otolaryngol Head Neck Surg, 2023, 168(4):745-753.
doi: 10.1177/01945998221095720
URL
|
[23] |
COOPER D S, SPECKER B, HO M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry[J]. Thyroid, 1998, 8(9):737-744.
doi: 10.1089/thy.1998.8.737
pmid: 9777742
|
[24] |
CARHILL A A, LITOFSKY D R, ROSS D S, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012[J]. J Clin Endocrinol Metab, 2015, 100(9):3270-3279.
doi: 10.1210/JC.2015-1346
pmid: 26171797
|
[25] |
HOVENS G C, STOKKEL M P, KIEVIT J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2007, 92(7):2610-2615.
doi: 10.1210/jc.2006-2566
URL
|
[26] |
SUGITANI I, FUJIMOTO Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papi-llary thyroid carcinoma? A randomized controlled trial[J]. J Clin Endocrinol Metab, 2010, 95(10):4576-4583.
doi: 10.1210/jc.2010-0161
URL
|
[27] |
PARK S, KIM W G, HAN M, et al. Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study[J]. Thyroid, 2017, 27(9):1164-1170.
doi: 10.1089/thy.2017.0177
pmid: 28699428
|
[28] |
XU S, HUANG Y, HUANG H, et al. Optimal serum thyrotropin level for patients with papillary thyroid carcinoma after lobectomy[J]. Thyroid, 2022, 32(2):138-144.
doi: 10.1089/thy.2021.0404
URL
|
[29] |
PARK J H, LEE Y M, LEE Y H, et al. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma[J]. J Surg Oncol, 2018, 118(3):390-396.
doi: 10.1002/jso.25164
pmid: 30114333
|
[30] |
LEE E K, KANG Y E, PARK Y J, et al. A multicenter, randomized, controlled trial for assessing the usefulness of suppressing thyroid stimulating hormone target levels after thyroid lobectomy in low to intermediate risk thyroid cancer patients (MASTER): a study protocol[J]. Endocrinol Metab (Seoul), 2021, 36(3):574-581.
doi: 10.3803/EnM.2020.943
URL
|
[31] |
ULLMANN T M, PAPALEONTIOU M, SOSA J A. Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis[J]. J Clin Endocrinol Metab, 2023, 108(2):271-280.
doi: 10.1210/clinem/dgac646
URL
|
[32] |
VERBURG F A, LUSTER M. Thyroid cancer: balancing benefit and risk in TSH management of DTC[J]. Nat Rev Endocrinol, 2018, 14(3):136-137.
doi: 10.1038/nrendo.2018.1
pmid: 29348477
|